Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07570979 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 208
- Enrollment target
NCT07570979 is a Phase 1 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 208 participants.
The verdict
NCT07570979, a Phase 1 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 208 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastatic prostate cancer.
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Androgen deprivation therapy (ADT)
- DRUG INR731
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2026-05-25 |
| Est. Completion | 2030-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07570979
The ClinicalTrials.gov registry entry for NCT07570979 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Enzalutamide is the first listed.
NCT07570979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07570979 about?
NCT07570979 is a clinical study titled "A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer". The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastati...
What is the current status of trial NCT07570979?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 208 participants. The study started on 2026-05-25. Estimated completion is 2030-06-03.
What interventions are being tested in trial NCT07570979?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), Androgen deprivation therapy (ADT) (DRUG), INR731 (DRUG).
Who is sponsoring clinical trial NCT07570979?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.